Safety of nimotuzumab following clinical trials in head and neck epithelial tumors
Context: Immunotherapy, by directing the immune response against tumor cells, complements the oncological therapy along with conventional treatments. Thus, the monoclonal antibody nimotuzumab blocks the binding of epidermal growth factor to its receptor, interfering with cell proliferation in epithe...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
GarVal Editorial Ltda.,
2021-05-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|